Do lipid profiles of postmenopausal women under oral hormone replacement therapy remain stable or reveal a multiphasic course in time?

References

• Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concen-trations and metabolism of lipoproteins. N Engl J Med 1991;325:1196–204
   PubMed Web of Science ®Google Scholar
• Lobo RA, Speroff L. International consensus conference on postmenopausal hormone therapy and the cardiovascular system. Fertil Steril 1994;61:592–5
   PubMed Web of Science ®Google Scholar
• Wild RA. Estrogens. Effects on the cardiovascular tree. Obstet Gynecol 1996;87:27–35
   PubMedGoogle Scholar
• The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEP I) Trial. J Am Med Assoc 1995;273:199–208
   Google Scholar
• Kessler CM, Szymanski LM, Shamsipour Z, et al. Estrogen replacement therapy and coagulation: relationship to lipid and lipoprotein changes. Obstet Gynecol 1997;8:326–31
   Google Scholar
• Ossewaarde ME, Bots ML, Bak AA, et al. Effect of hormone replacement therapy on lipids in pen-menopausal and early postmenopausal women. Maturitas 2001;39:209–16
   PubMed Web of Science ®Google Scholar
• Godsland IF. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. Fertil Steril 2001; 75:898–915
   PubMed Web of Science ®Google Scholar
• Watts NB, Notelovitz M, Timmons MC, et al. Comparisons of oral estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid—lipoprotein profiles in surgical menopause. Obstet Gynecol 1995;85:529–37
   PubMed Web of Science ®Google Scholar
• Limacher MC. Issues of hormone replacement therapy and cardiovascular disease for elderly women. Am J Geriatr Cardiol 2002;11:217–22
   PubMedGoogle Scholar
• Hulley S, Furberg C, Barrett-Connor E, et al. HERS Research Group. Noncardiovascular disease outcomes during 6.8 years ofhomione therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). J Am Med Assoc 2002;288: 58–66
   Google Scholar
• Albertazzi P, Di Micco R, Zanardi E. Tibolone: a review. Maturitas 1998;16:295–305
   Google Scholar
• Klein KP, Herrington DM. Effects of estrogen and selective estrogen receptor modulators on indicators of cardiovascular health in postmenopausal women. Medscape Worn Health 2002;7:2
   PubMedGoogle Scholar
• Heckbert S, Kaplan R, Weiss, N, et al. Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy. Arch Intern Med 2001;161:1709–13
   PubMed Web of Science ®Google Scholar
• Gorelick PB, Sacco RL, Smith DB, et al. Prevention of a first stroke. A review of guidelines and a multi-disciplinary consensus statement from the National Stroke Association. J Am Med Assoc 1999;281: 1112–20
   PubMed Web of Science ®Google Scholar
• Albers G, Hart R, Lutsep HL, et al. AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 1999; 30:2502–11
   Google Scholar
• Gotto A. Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol. Arch Intern Med 1999;159:1038–40
   PubMedGoogle Scholar
• Baker G, de Bacquer D, Kornitzer M. Epidemio-logical aspects of high density lipo-protein cholesterol. Atherosclerosis 1998;137:S1–6
   PubMedGoogle Scholar
• Kwiterovich P. The antiatherogenic role of high-density lipoprotein cholesterol. AmJ Cardiol 1998;82: 13Q–21Q
   Google Scholar
• Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Munster Study. Am J Cardiol 1992;70:733–7
   PubMed Web of Science ®Google Scholar
• Castelli W. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol 1998;4:5A–10A
   Google Scholar
• Austin MA, Hokanson JE, Edwards KL. Hyper-triglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B–12B
   Google Scholar
• Baracat EC, Barbosa IC, Giordano MG, et al. A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 2002;5:60–9
   PubMed Web of Science ®Google Scholar
• Prelevic GM, Bebic T, Balint-Peric L, et al. Metabolic effects of tibolone in postmenopausal women with non-insulin dependent diabetes mellitus. Maturitas 1998;28:271–6
   Google Scholar
• Writing Group for the WHI Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Intitiative randomized controlled trial. J Am Med Assoc 2002;288:321–33
   Google Scholar
• Mosca L, Collins P, Herrington DM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 2001;104: 499–503
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Gambacciani M, International Menopause Society. Controversial issues in climacteric medicine I. Cardiovascular disease and hormone replacement therapy. International Meno-pause Society Expert Workshop, 13–16 October 2000, Royal Society of Medicine, London, UK. Climacteric 2000;3: 233–40
   Google Scholar
• Cetinkya MB, Alper T, Kokcu A, et al. Tibolone versus four estrogen replacement protocols and plasma lipid levels in postmenopausal women. Int J Gynecol Obstet 2002;79:17–23
   PubMed Web of Science ®Google Scholar
• Kiikça A, etinkaya MB, Yanik F, et al. The comparison of effects of tibolone and conjugated estrogen—medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 2000;36:75–80.
   Google Scholar